YOLFTbeta
Actinogen Medical Ltd

Actinogen Medical Ltd

ACW · AU · Healthcare / Biotechnology

0.045AUD-0.00 (-4.26%)

Price History

Full chart

Market Stats

Previous Close0.047
Open0.048
Day Range0.045 – 0.049
52-Week Range0.028 – 0.072
Volume8.47M
Market Cap209.21M
P/E (TTM)0.00
Forward P/E25.97
EPS0.00
Dividend Yield0.00%
Beta0.89
50-Day Avg0.0496
200-Day Avg0.0443

About

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.
  • Employees0
  • Headquarters109 Pitt Street, Sydney, NSW, Australia, 2000, Australia
  • Websitehttps://actinogen.com.au

Leadership

  • Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.MD, CEO & Director · b. 1959
  • Mr. William Edward Souter BCom, IPAA, LLB (Adel)Chief Financial Officer
  • Dr. Dana C. Hilt M.D.Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board · b. 1953
  • Mr. Andrew B. Udell B.Sc., M.B.A.Chief Commercial Officer · b. 1970
  • Mr. Michael RobertsHead of Investor Relations & Corporate Communications
  • Prof. Paul Edward Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.Head of Clinical Pharmacology & Lead Physician and Depression · b. 1956
  • Dr. Fujun Li Ph.D.Head of Manufacturing
  • Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · b. 1963

Financials

Income Statement

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue--155.88K128.13K92.80K94.45K51.56K3.10K181.20K153.43K3.95M1.42M3.30M4.86M3.52M1.98M3.64M4.89M9.93M5.49M-
Growth (%)----17.80%-27.57%+1.78%-45.41%-93.98%+5741.52%-15.33%+2476.40%-64.19%+133.19%+47.32%-27.69%-43.58%+83.47%+34.28%+103.18%-44.73%-
Cost of Revenue--18.00K219.00K405.00K391.00K427.00K257.00K00365.33K360.62K356.04K353.50K412.93K386.69K400.67K405.61K416.83K422.20K419.27K
Gross Profit--155.88K128.13K92.80K94.45K51.56K3.10K181.20K153.43K3.59M1.05M2.94M4.51M3.10M1.60M3.24M4.48M9.93M5.49M-419.27K
Gross Margin--100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%90.76%74.52%89.21%92.73%88.26%80.51%88.99%91.70%100.00%100.00%-
Operating Expense--733.32K1.01M1.10M1.15M1.16M460.50K598.18K5.58M11.17M5.65M12.51M14.12M12.02M7.50M16.41M20.36M22.77M20.42M27.69M
Operating Income---577.44K-884.17K-1.01M-1.05M-1.11M-457.39K-416.98K-5.42M-7.58M-4.60M-9.56M-9.61M-8.91M-5.90M-13.17M-15.87M-12.84M-14.93M-28.11M
Operating Margin---370.45%-690.08%-1083.19%-1112.80%-2152.49%-14745.10%-230.12%-3535.55%-191.76%-324.79%-289.70%-197.57%-253.44%-297.57%-361.90%-324.74%-129.28%-272.01%-
EBITDA---434.04K-1.06M-900.10K-1.01M-1.77M-438.01K-426.63K-5.20M-3.26M-2.82M-5.91M-9.25M-8.20M-5.35M-12.72M-15.22M-12.84M-15.01M-27.69M
EBITDA Margin---278.45%-831.11%-969.93%-1064.53%-3427.23%-14120.25%-235.44%-3391.23%-82.52%-199.31%-178.92%-190.30%-233.30%-269.42%-349.40%-311.34%-129.28%-273.48%-
Net Income---435.66K-926.94K-737.47K-742.38K-1.53M-164.66K-440.22K-5.43M-3.63M-3.19M-6.23M-9.89M-5.33M-3.92M-9.50M-10.75M-13.04M-14.73M-15.38M
Net Income Margin---279.49%-723.46%-794.68%-785.98%-2965.66%-5308.28%-242.94%-3539.75%-91.93%-225.39%-188.76%-203.33%-151.59%-197.32%-260.91%-219.98%-131.34%-268.37%-
R&D-------289.16K218.68K2.76M5.61M3.19M7.74M10.90M5.54M2.41M8.21M8.90M15.54M12.30M19.03M
R&D as % of Total Revenue-------9321.70%120.68%1797.80%142.00%225.40%234.54%224.06%157.47%121.28%225.68%182.08%156.43%224.00%-
Interest Expense00454578051.08K1.01K7157224.95K6.43K8.53K11.46K7.99K28.88K22.32K18.48K16.60K24.29K48.89K465.94K
Interest Expense % of Total Revenue--0.29%0.04%0.87%1.14%1.96%23.05%0.40%3.23%0.16%0.60%0.35%0.16%0.82%1.12%0.51%0.34%0.24%0.89%-

Balance Sheet

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets53.00K268.00K2.94M2.01M1.34M1.14M465.80K275.67K1.26M15.58M12.95M10.21M18.03M16.22M11.94M18.38M23.31M15.21M21.31M24.48M29.56M
Total Liabilities29.00K60.00K82.33K105.42K173.58K94.68K118.81K81.32K49.93K222.64K824.20K844.26K768.25K557.39K1.05M920.32K1.57M1.80M1.62M6.15M8.18M
Total Equity24.00K208.00K2.86M1.90M1.17M1.05M346.99K194.35K1.21M15.36M12.13M9.37M17.26M15.66M10.89M17.46M21.74M13.41M19.70M18.34M21.37M
Cash44.00K48.00K2.54M1.85M1.09M861.18K203.74K112.52K1.13M9.81M751.98K1.89M9.90M7.64M5.04M13.42M16.37M8.46M9.45M16.50M16.73M
Total Debt-------------389.87K389.87K236.44K165.27K86.93K319.07K3.26M4.78M
Net Debt---2.54M-1.85M-1.09M-861.18K-203.74K-112.52K-1.13M-9.81M-751.98K-1.89M-9.90M-7.64M-4.65M-13.19M-16.21M-8.37M-9.13M-13.24M-11.95M

Cash Flow

Currency: AUD2006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow---397.22K-546.87K-727.37K-805.70K-823.94K-125.56K-437.84K-3.72M-5.04M-1.11M-7.91M-10.50M-2.86M-1.72M-9.52M-8.70M-16.95M-7.56M-17.56M
Investing Cash Flow---309.07K-144.62K-36.92K-16.32K-2.09K22.32K-4.68K28.45K-4.01M1.98M1.95M71.77K-22.76K-6.19K-2.94K-36.60K-8.16K-38.02K-9.29K
Financing Cash Flow258.00K597.00K3.22M--597.83K168.58K12.03K1.46M12.37M270.00K270.00K13.96M8.17M282.26K10.11M12.42M824.62K17.95M14.65M17.80M
Capital Expenditure7.00K09.07K122.62K58.92K16.32K2.33K04.68K8.12K12.46K1.02K27422.76K22.76K6.19K2.94K36.60K8.16K38.02K9.29K
Free Cash Flow---406.30K-669.49K-786.28K-822.03K-826.27K-125.56K-442.52K-3.73M-5.05M-1.11M-7.91M-10.50M-2.88M-1.73M-9.52M-8.73M-16.96M-7.59M-17.57M
Dividends Paid----------00--10.20M360.00K11.59M6.67K---
FCF to OCF--102.28%122.42%108.10%102.03%100.28%100.00%101.07%100.22%100.25%100.09%100.00%100.00%100.80%100.36%100.03%100.42%100.05%100.50%100.05%
Dividend Paid to FCF----------0.00%0.00%---354.21%-20.81%-121.73%-0.08%---

Earnings

Report DateFeb 19, 2016Aug 31, 2016Feb 27, 2017Aug 18, 2017Feb 15, 2018Aug 29, 2018Feb 22, 2019Aug 16, 2019Feb 20, 2020Aug 26, 2020Feb 24, 2021Aug 24, 2021Feb 22, 2022Aug 25, 2022Feb 22, 2023May 31, 2023Aug 30, 2023Oct 13, 2023Feb 25, 2024May 29, 2024Aug 29, 2024Nov 27, 2024Feb 24, 2025May 28, 2025Aug 25, 2025Dec 3, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual0.000.000.000.00-0.010.00-0.010.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Surprise--------------------------
Timing-------------After-hoursAfter-hours-After-hoursAfter-hours--------

Key Statistics & Ratios

Market Cap209.21M
Enterprise Value215.07M
Trailing P/E0.00
Forward P/E25.97
PEG Ratio0.00
Price / Sales16.51
Price / Book10.62
EPS0.00
Book Value0.006
Revenue (TTM)12.67M
Gross Profit (TTM)12.67M
EBITDA-15.10M
Profit Margin-121.35%
Operating Margin-37.34%
Return on Equity-77.46%
Return on Assets-35.71%
Shares Outstanding3.87B
Shares Float3.13B
Beta0.89
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 9, 2024512:505
  • Aug 11, 20231013:973
  • Oct 19, 202050:49
  • Dec 3, 20131:2
  • Oct 12, 201022:19